Piper Sandler on TransMedics Group (TMDX): 'Assessing the $2.2B U.S. Kidney Opportunity'

July 22, 2026 9:26 AM

Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $120.00 price target on TransMedics Group (NASDAQ: TMDX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found